Glaukos Corporation
GKOS
株式のランク
#2017
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
株価
$174.32
時価総額
$10.28B
変化（1日）
4.51%
変化（1年）
119.35%
国
US
取引 Glaukos Corporation (GKOS)
カテゴリー
Healthcare
Glaukos Corporation（GKOS）の発行済株式数
June 2026 時点の発行済株式数 58.42M
Glaukos Corporation の最新の財務報告および株価によると、現在の発行済株式数は 58.42M です。December 2023 の終わりには、同社は 48.43M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Glaukos Corporation（GKOS）の発行済株式数の履歴（2012 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 58.42M | 10.74% |
| 2024 | 52.76M | 8.92% |
| 2023 | 48.43M | 2.08% |
| 2022 | 47.44M | 2.20% |
| 2021 | 46.42M | 4.33% |
| 2020 | 44.50M | 19.12% |
| 2019 | 37.36M | 6.72% |
| 2018 | 35.00M | 1.81% |
| 2017 | 34.38M | 4.41% |
| 2016 | 32.93M | 88.44% |
| 2015 | 17.47M | -29.78% |
| 2014 | 24.89M | 0.00% |
| 2013 | 24.89M | 1,153.02% |
| 2012 | 1.99M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 1.74B | 2,883.70% |
US
|
|
| 1.28B | 2,094.66% |
IE
|
|
| 383.50M | 556.46% |
US
|
|
| 1.48B | 2,429.31% |
US
|
|
| - | - |
DE
|
